Dr. Yan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4721 Dallas Ranch Rd
Antioch, CA 94531Phone+1 925-778-0679Fax+1 925-778-3567
Education & Training
- Case Western Reserve UniversityPh.D., Molecular Biology and Microbiology, 1999 - 2005
- Peking Union Medical CollegeClass of 1998
- Shandong Medical UniversityB.Sc., Medical Science, 1990 - 1996
Certifications & Licensure
- CA State Medical License 2011 - 2026
Awards, Honors, & Recognition
- 2nd Place, Resident Research Abstract Competition New York Chapter, American College of Physicians, 2011
- Oncology Young Investigator Award AACR-Bristol-Myers Squibb, 2005
- Award for Cancer Research Milheim Foundation, 2005
Publications & Presentations
PubMed
- 4 citationsDalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial.Min Yan, Limin Niu, Huimin Lv, Mengwei Zhang, Jing Wang
Nature Communications. 2023-10-07 - 18 citationsAndrogen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity.Xiaomin Zhang, Limin Cheng, Chengqi Gao, Jing Chen, Shuangye Liao
Cancer Research. 2023-03-15 - 9 citationsPamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.Binghe Xu, Tao Sun, Yanxia Shi, Jiuwei Cui, Yongmei Yin
Breast Cancer Research and Treatment. 2023-02-01
Journal Articles
- HER2 aberrations in cancer: Implications for therapyYan M, Parker BA, Schwab R, Kurzrock R, Cancer Treat Rev, 7/1/2014
- Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesisChoi SH, Kim BG, Robinson J, Fink S, Yan M, Sporn MB, Markowitz SD, Letterio JJ, J Clin Invest, 6/1/2014
- CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximabYan M, Dong Z, Zhao F, Chauncey T, Deauna-Limayo D, Wang-Rodriguez J, Liu D, Wang HY, Pilz R, Eur J Haematol, 2/14/2014
- Join now to see all
Abstracts/Posters
- HER2 distribution in diverse tumors: Analysis of 11,493 nonbreast, nongastric cancers.David Arguello, Sherri Z. Millis, Zoran Gatalica, Min Yan, Razelle Kurzrock, J Clin Oncol, 1/1/2014
- Prostaglandin Transporter, Down-Regulated In Colon Cancer, Mediates Prostaglandin Influx For Intracellular Degradation. Poster.Yan M, Markowitz S, Annual Meeting of Medical Society of the State of New York, Rochester, NY, 1/1/2009
- 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Poster.Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, Luo G, Hensold J, Tai HH, Wilson K, Markowitz SD, AACR Annual Meeting, 1/1/2005
Press Mentions
- Prof. Yongmei Yin at 2023 ESMO: SKB264 (MK-2870), an innovativeTROP2-ADC Originating from Chinese Biotech, Achieves Remarkable Success in Overcoming the Therapeutic Impasse in HR+/HER2- Metastatic Breast CancerOctober 27th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: